Neratinib for treating HER2-positive breast cancer after 2 therapies [ID1381]
Discontinued
Reference number: GID-TA10539
Please note that following on from advice received from the company, the timelines for this appraisal remain to be confirmed. Further information regarding the scheduling of this appraisal will be available in due course.